Friday, March 28, 2014

TDCJ Will Appeal Judge's Ruling on Execution Drugs

Amid national debate over the disclosure of information about drugs used in executions, Texas Department of Criminal Justice officials said Thursday that they will appeal a judge’s order to disclose the supplier of a new batch of its execution drugs.
“We are disappointed in the district court's decision and will be appealing the ruling to a higher court,” TDCJ spokesman Jason Clark said in an email.

continue to read here

Imprimis Announces Compounding Pharmacy Strategy

Compounding Pharmacy Strategy


One of our key strategies is the use of compounding pharmacies to formulate our proprietary compounded drug formulations and technologies and distribute them to physicians and patients.  Governed by state and federal statutes and regulations, including the Drug Quality and Security Act of 2013 (DQSA), compounding pharmacies work with physicians to develop medications for individually identified patients. Examples of compounded formulations include medications with alternative dosage strengths or unique dosage forms, such as topical creams or gels, suspensions or solutions with more tolerable drug delivery vehicles.  A physician may also work together with a pharmacist to repurpose or reformulate FDA-approved drugs via the compounding process to meet a patient’s specific medical needs.  We are strategically attentive to the ideas generated by pharmacists dealing directly with doctors and their patients to address specific and often unmet patient needs, and we believe in and support the important role and contribution of the compounding pharmacist and compounding pharmacies in the U.S. healthcare system.

quoted from here

UPDATE! Compounding Registered Outsourcing Facilities

Compounding Registered Outsourcing Facilities

Concern About Authenticity of Alli

03/27/2014Alli Alli Weight Loss Product Concerns about authenticity of product

GlaxoSmithKline (GSK) Consumer Healthcare
source found here


 

Save the Date for the American Society for Pharmacy Law Developments in Pharmacy Law Seminar XXV

American Society for Pharmacy Law
Developments in Pharmacy Law Seminar XXV

November 69, 2014

Hyatt Regency Indian Wells Resort & Spa
Indian Wells, California

 Interested in sponsoring the ASPL DPLXXV Seminar?
Click here for more information.

Thursday, March 27, 2014

IACP Summarizes the FDA Fiscal Year 2015 Budget

The President released his budget on March 4th, requesting $4.7 billion for the Food and Drug Administration (FDA), which is $358 million, or 8% above the FY 2014 Enacted level. The President specifically requested $25 million of the total for agency-wide oversight of drug compounding, including enforcement, inspections, and collaboration with States.
Click here to read IACP's Summary of the FDA FY 2015 Budget http://bit.ly/1gueIZE

PETA Makes Case; Medication Reforms Touted

PETA Makes Case; Medication Reforms Touted

PETA Video Fallout and Horse Doping Issues Continue to be a huge topic--Here are Some Must Reads for those Dealing With Horse Doping and Veterinary Compounding Issues

PETA video fallout and reaction continues:
.
>>> Zayat press release: "Then Scott Blasi texted me Friday night ... 'I want to apologize ... I was clearly under the influence of alcohol and a woman."
>>> Ehalt: "The report has been both hailed and assailed ... And the truth is somewhere in the middle."
>>> Pricci: "Racing on hay, oats and water is the only remedy that's acceptable now, the general public will demand no less, nor should they."
>>> PETA VP: "It's time for the U.S. Anti-Doping Agency to step in and clean up the thoroughbred racing industry's addiction to drugs."
>>> Sulky side blog: "So based on the reaction thus far, can we draw any conclusions for harness racing?"
>>> MacAdam: "All ripping PETA does is deflect attention from the fact that racing continues to be its own worst enemy."
>>> Towers' Pull the Pocket blog offer some on-going commentary
>>> Scribe from the New Orleans area: Thought, feelings, observations on Asumussen video scandal
>>> Noonan: Yet another wake-up call for racing>>> Owner Zayat transferring horses from Asmussen stable
>>> The Atlantic/Cohen: The ugly truth about horse racing... An expose by PETA, published in The New York Times, shows a side of the sport that the industry has tried hard to shield from public view
>>> Jicha: "If this forces racing to step up and finally take meaningful action to clean up the game, it could be worth this latest embarrassment. The question is how."
>>> Scott: "One thing is certain - the time remaining for racing to put its house in order, on more or less its own terms, just got a whole lot shorter."
>>> TDN commentary: "What is required right now is for tracks and owners to sit down and write our Declaration of Independence."
>>> Top Australian vet suggests common practices in the US racing are alarming by international standards 

KPIC Training Courses Planned for 2014 - Kennedy Pharmacy ...

kennedycenter.sc.edu/.../KPIC-ACE_Mailer-...
University of South Carolina
Loading...
23 hours ago - All courses are conducted at the state-of-the-art Aseptic Compounding Experience (ACE) Lab at the South Carolina College of Pharmacy in Columbia. Kennedy ...

IACP Town Hall Meeting Update


ABA Civil False Claims Act 2014 CLE


 
  • Meeting Materials

  • Program Description

The Civil False Claims Act (FCA) is the fastest growing area of federal litigation, particularly because of its unique qui tam enforcement mechanism. Amendments in 2009 made this law even more powerful. The 10th Annual National Institute on the Civil False Claims Act and Qui Tam Enforcement will bring together experts from all areas—U.S. Department of Justice, state attorney general offices, federal agencies, leading defense and plaintiff firms—to discuss this ever-growing area of litigation and enforcement.

11th Annual Washington Health Law Summit Materials

11th Annual Washington Health Law Summit Materials

11th Annual Washington Health Law Summit Materials
Product Code:5630124PDF
Publication Date:February 2014
Sponsoring Entities:Health Law Section
Topics:Health Law
Format:PDF - 5630124PDF
Pricing:$250.00 (Regular)
$175.00 (ABA Member) ABA Members, Log in now to receive this discount!
$125.00 (Health Law Section) ABA Members, Log in now to receive this discount!
Quantity:
 
About the Washington Health Law Summit

The Washington Health Law Summit serves to bring attendees up to date on the latest legislative and policy developments and the implementation of significant healthcare initiatives emanating from HHS, CMS, IRS, DOJ, OIG and other key government agencies.
Accessing Your Download after Purchase

Immediately after checkout, the download file(s) will be available in Your Downloads (accessible in the left navigation area of the Web Store when logged in).

ABA Health Care Fraud National Institute May 14-16, 2014

Learn one-on-one from regulators, prosecutors and criminal defense attorneys.
Register today for the 24th Annual National Institute on Health Care Fraud.
Health Care Fraud National Institute
May 14-16, 2014
Hotel Nikko
San Francisco, CA
15.75 CLE Credits Requested
This CLE National Institute is perfect for health care attorneys, compliance professionals, regulators, prosecutors, criminal defense attorneys and qui tam regulators' counsel.Attendees of this National Institute will:
  • Increase their knowledge of current legal and ethical issues that health care fraud practitioners face daily
  • Gain practical knowledge about current enforcement actions and priorities
  • Participate in specialty workshops designed to address the needs of practitioners at every level of competence

2 easy ways to learn more and register
Visit us onlineVisit us online
Call the ABA at 800-285-2221Call the ABA at 800-285-2221

Wednesday, March 26, 2014

SDCVMA Spring Confrence


 
Join us in San Diego SDCVMA spring conference.
Click here for details!

Connecticut VMA

Connecticut VMA
4/1/2014 - 4/2/2014

Join us Tuesday April 1st and 2nd at the Connecticut Convention Center and the Connecticut Science Center. 
Click here for details!

Question of the Day March 26, 2014 Is it a conflict of interest for a veterinary compounding representative or marketing representative to serve on the board of the state veterinary medical association? Why or why not?


Long Island Veterinary Medical Association Holding CE on SUNDAY, April 6 - All Day CE -on legalities of veterinary compounding--presenter is Coy Privette From Roadrunner Pharmacy; Privette serves as a board member on the North Carolina and Virginia Veterinary Medical Associations

2:40pm-3:40pm
Coy Privette A graduate from the University of North Carolina at Chapel Hill, Coy was commissioned to serve in the United States Army after college and was deployed for Operation Enduring Freedom as a Field Artillery Officer during the initial rotations into Afghanistan. He joined the veterinary community in 2005 as a territory manager for Roadrunner Pharmacy in North Carolina and Virginia. He has been the Eastern Regional Manager since 2009 and has served as a board member for both the North Carolina and Virginia Veterinary Medical Associations. He has been integral in the state to state legalities of compounding veterinary medications for Roadrunner Pharmacy and has helped create state by state compliance standards inside the pharmacy. Coy was the point person that worked with the AVMA while they were crafting their stance on veterinary compounding and the requirements of compounding pharmacies on a national level, and he has been giving legality talks to veterinary organizations based on their individual state board requirements for much of the Eastern United States for the past five years. Coy resides in North Carolina with his wife, two young sons, and their lab Baxter.

more information found here

FDA Enforcement Report Week of March 26, 2014 for Drugs

Drugs Clalis capsules, 50 mg, 6 -count bottle ( labeling is in foreign language) All lots Class I Marketed without an Approved NDA/ANDA: Laboratory analysis conducted by the FDA has determined that the products was found to contain sildenafil, an undeclared active pharmaceutical ingredient. Fabscout Entertainment, Inc
Drugs Silver Sword capsules, 180 mg, 16-count clamshell tin, UPC 1 234658 970128 12345 (labeling is in foreign language) All lots Class I Marketed without an Approved NDA/ANDA: Laboratory analysis conducted by the FDA has determined that the products was found to contain sildenafil, an undeclared active pharmaceutical ingredient. Fabscout Entertainment, Inc
Drugs Marcaine (bupivacaine HCl) injection, USP, 0.25%, 30 mL single-dose vials-preservative free, packaged in 10-count vials per carton, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-1559-30. Lot 25-220-DD, Exp 1JAN2015 Class I Presence of Particulate Matter: Units of this lot may have visible metal particles embedded in the vial and in the solution causing the product to be discolored. Hospira Inc.
Drugs 5% Dextrose Injection, USP, 100 mL Single dose VIAFLEX plastic containers, Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, Product code 2B0089, NDC 0338-0017-38. Lot #: P285288, Exp 11/13 Class I Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution. Baxter Healthcare Corp.
Drugs 0.9% Sodium Chloride Injection, USP, packaged in a) 50 mL Single dose VIAFLEX plastic containers (Product code 2B1308, NDC 0338-0049-31) and b) 100 mL Single dose VIAFLEX plastic containers (Product code 2B1302, NDC 0338-0049-18) and (Product code 2B1309, NDC 0338-0049-38), Rx only, Baxter Healthcare Corporation, Deerfield, IL 60015 USA. Lot #: a) P297283, Exp 08/14; b) P292326, Exp 04/14; P293993, Exp 05/14; and P293514, Exp 04/14 Class I Presence of Particulate Matter: Baxter is issuing a voluntary recall for these IV solutions due to particulate matter found in the solution. Baxter Healthcare Corp.
Drugs Clinimix 4.25/25 sulfite-free (4.25% Amino Acid in 25% Dextrose) Injection, 1000 mLCLARITY Dual Chamber Container bag, Rx only. Dist: Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL 60015. NDC: 0338-1115-04. Lot#: P287045, Exp 6/2014 Class I Presence of Particulate Matter: Particulate matter includes wood, sodium citrate and dextrose. Baxter Healthcare Corp.
Drugs Clinimix E 4.25/10 sulfite-free (4.25% Amino Acid with Electrolytes in 10% Dextrose with Calcium) Injection, 2000 mL CLARITY Dual Chamber Container bag, Rx only. Dist: Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL 60015. NDC 0338-1115-04. Lot#: P275883, Exp 10/2013 Class I Presence of Particulate Matter: Particulate matter includes wood, sodium citrate and dextrose. Baxter Healthcare Corp.
Drugs Clinimix 5/15 sulfite-free (5% Amino Acid in 15% Dextrose) Injection, 2000 mL CLARITY Dual Chamber Container bag, Rx only. Dist: Baxter Healthcare Corporation, One Baxter Parkway, Deerfield, IL 60015. NDC: 0338-1099-04. Lot# P285122, Exp 5/2014 Class I Presence of Particulate Matter: Particulate matter includes wood, sodium citrate and dextrose. Baxter Healthcare Corp.
Drugs Hydroxyprogesterone Caproate 250mg/ml in Sesame Oil, 1 ml injectable solution, in 3 ml single dose syringes; a multi-ingredient compounded medication in bulk, containing Benzoyl Benzoate USP 0.46 ml/1ml, and Benzyl Alcohol 0.02 ml/1ml; syringe is labeled in part ***FOR INJECTION USE ONLY***RX South LLC DBA RX3 12230 Iron Bridge Rd Chester, VA 23831*** Lot number: 12052013:03 Expiration date: 06/03/2014 Class II Crystallization; visible crystals from the active ingredient formed due to extreme cold temperatures during shipping RX South LLC DBA RX3 Pharmacy
Drugs Advil PM Caplets, (Ibuprofen, 200 mg /Diphenhydramine citrate, 38 mg) 120 count bottle, OTC, Pfizer, Madison, NJ 07940 USA. NDC 0573-0164-43 G85041 Class III Subpotent Drug: This lot is being recalled because of out-of-specification test results for Diphenhydramine citrate. Pfizer Us Pharmaceutical Group
Drugs Guaifenesin USP, 50 Kg Drums, CAS No. 93-14-1, Reg. No. 05436, Caution: For Manufacturing, Processing, or Repacking, Delta Synthetic Co., Ltd. 15, Minsheng St., Tucheng Dist., New Taipei City, 23679, Taiwan (ROC), NDC 60203-1001 211J3291 211J3292 211K3293 211K3294 211K3295 211K3297 211K3298 211K3299 211K3301 211K3302 211K3315 211K3321 211K3322 Class II Presence of Foreign Matter: Guaifenesin API powder is being recalled due to the possibility that the product contains polyethylene fibers from a screen used to sift the Guaifenesin. Traxx International Corp
Drugs Daytrana (methylphenidate) transdermal system patch, Delivers 20 mg over 9 hours (2.2mg/hr), 1 patch per pouch , packaged in 30-count patches per box, Rx Only. Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5554-3. Lot #69618, Exp. 09/14 Class II Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained. Noven Pharmaceuticals, Inc.
Drugs Daytrana (methylphenidate) transdermal system patch, Delivers 30 mg over 9 hours (3.3mg/hr), 1patch per pouch , packaged in 30-count patches per box, Rx Only.Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceuticals, Inc., Miami, FL 33186. NDC 68968-5555-3. Lot #70132, Exp. 09/14 Class II Defective Delivery System: Out of Specification (OOS) results for the z-statistic value, which relates to the patients and caregiver ability to remove the release liner from the patch adhesive prior to administration, were obtained. Noven Pharmaceuticals, Inc.
Drugs Perrigo, Clindamycin Palmitate Hydrochloride for Oral Solution, USP, 75mg/5mL, 100 ml, NDC 0574-0129-01 2013313915 Exp 08/15, 2013374398 Exp 09/15, 2013323969 Exp 08/15, 2013364336 Exp 09/15, 2013323971 Exp 08/15, 2013364334 Exp 09/15, 2013313913 Exp 08/15 Class II Presence of Particulate Matter Perrigo is recalling seven lots of Clindamycin Palmitate Hydrochloride for Oral Solution 75mg/5ml. Paddock Laboratories, LLC
Drugs Venlafaxine Hydrochloride, Extended Release Capsules, 150 mg, UD-100 Tablets per Box (10 x 10), Rx Only, Manufactured by: Teva Pharmaceuticals USA, 1090 Horsham Rd, North Wales, PA 19454, NDC 63739-0512-10 Lot #: 91357 Class III Failed Dissolution Specification: Out of Specification dissolution results at 12 month interval. McKesson Packaging Services